{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:44:00Z","timestamp":1793519040825,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,23]]},"DOI":"10.7759\/cureus.77872","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:06:51Z","timestamp":1737641211000},"source":"Crossref","is-referenced-by-count":5,"title":["Hemorrhagic Pericardial Effusion and Cardiac Tamponade in B-chronic Lymphocytic Leukemia Treated With Ibrutinib: A Case Report"],"prefix":"10.7759","author":[{"given":"James C","family":"Barton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi F","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Cavender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002805","article-title":"Cardiovascular adverse events of ibrutinib","volume":"134","author":"Ahn IE","year":"2019","unstructured":"Ahn IE. Cardiovascular adverse events of ibrutinib. Blood. 2019, 134:1881-2. 10.1182\/blood.2019002805","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.262063","article-title":"Relative selectivity of covalent inhibitors requires assessment of inactivation kinetics and cellular occupancy: a case study of ibrutinib and acalabrutinib","volume":"372","author":"Hopper M","year":"2020","unstructured":"Hopper M, Gururaja T, Kinoshita T, Dean JP, Hill RJ, Mongan A. Relative selectivity of covalent inhibitors requires assessment of inactivation kinetics and cellular occupancy: a case study of ibrutinib and acalabrutinib. J Pharmacol Exp Ther. 2020, 372:331-8. 10.1124\/jpet.119.262063","journal-title":"J Pharmacol Exp Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky JA","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, et al.. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013, 122:2539-49. 10.1182\/blood-2013-06-507947","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0923","article-title":"Ibrutinib inhibits ERBB receptor tyrosine kinasess and HER2-amplified breast cancer cell growth","volume":"15","author":"Chen J","year":"2016","unstructured":"Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L. Ibrutinib inhibits ERBB receptor tyrosine kinasess and HER2-amplified breast cancer cell growth. Mol Cancer Ther. 2016, 15:2835-44. 10.1158\/1535-7163.MCT-15-0923","journal-title":"Mol Cancer Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky AH","year":"2015","unstructured":"Lipsky AH, Farooqui MZ, Tian X, et al.. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015, 100:1571-8. 10.3324\/haematol.2015.126672","journal-title":"Haematologica"},{"key":"ref6","article-title":"Abstract 11835: Evaluation of cardiovascular adverse events associated with ibrutinib, venetoclax and idelalisib used in treatment of chronic lymphocytic leukemia","volume":"138","author":"Mahida H","year":"2018","unstructured":"Mahida H, Gharia B, Ugoeke N, Maludum O, Asif A, Calderon D. Abstract 11835: Evaluation of cardiovascular adverse events associated with ibrutinib, venetoclax and idelalisib used in treatment of chronic lymphocytic leukemia. Circulation. 2018, 138:11835.","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A3488","article-title":"Hemorrhagic pericardial effusion an unreported complication of ibrutinib","volume":"199","author":"Patel A","year":"2019","unstructured":"Patel A, Alvi N, Abraham RZ. Hemorrhagic pericardial effusion an unreported complication of ibrutinib. Am J Resp Crit Care Med. 2019, 199:3488. 10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A3488","journal-title":"Am J Resp Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2020.2020.0446","article-title":"Ibrutinib-induced cardiac tamponade in chronic lymphocytic leukemia","volume":"38","author":"Kidoguchi K","year":"2021","unstructured":"Kidoguchi K, Kubato Y, Nishimura Y, Kizuka-Sano H, Kimura S. Ibrutinib-induced cardiac tamponade in chronic lymphocytic leukemia. Turk J Haematol. 2021, 38:83-5. 10.4274\/tjh.galenos.2020.2020.0446","journal-title":"Turk J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytx018","article-title":"Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series","volume":"1","author":"Nassif T","year":"2017","unstructured":"Nassif T, Banchs J, Yusuf SW, Mouhayar E. Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series. Eur Heart J Case Rep. 2017, 1:ytx018. 10.1093\/ehjcr\/ytx018","journal-title":"Eur Heart J Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000775","article-title":"Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (Imbruvica) and interaction with direct oral anticoagulant","volume":"25","author":"Khalid M","year":"2018","unstructured":"Khalid M, Khattak F, Ramu V. Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (Imbruvica) and interaction with direct oral anticoagulant. Am J Ther. 2018, 25:e768-9. 10.1097\/MJT.0000000000000775","journal-title":"Am J Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4282486","article-title":"Ibrutinib-associated cardiac tamponade with concurrent antiplatelet therapy","volume":"2020","author":"Miatech JL","year":"2020","unstructured":"Miatech JL, Hughes JH, McCarty DK, Stagg MP. Ibrutinib-associated cardiac tamponade with concurrent antiplatelet therapy. Case Rep Hematol. 2020, 2020:4282486. 10.1155\/2020\/4282486","journal-title":"Case Rep Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02905.x","article-title":"Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females","volume":"114","author":"Futatani T","year":"2001","unstructured":"Futatani T, Watanabe C, Baba Y, Tsukada S, Ochs HD. Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol. 2001, 114:141-9. 10.1046\/j.1365-2141.2001.02905.x","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14943","article-title":"Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib","volume":"18","author":"Dmitrieva EA","year":"2020","unstructured":"Dmitrieva EA, Nikitin EA, Ignatova AA, et al.. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. J Thromb Haemost. 2020, 18:2672-84. 10.1111\/jth.14943","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1730080","article-title":"Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction","volume":"25","author":"Ninomoto J","year":"2020","unstructured":"Ninomoto J, Mokatrin A, Kinoshita T, et al.. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. Hematology. 2020, 25:112-17. 10.1080\/16078454.2020.1730080","journal-title":"Hematology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel S","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, et al.. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015, 29:783-7. 10.1038\/leu.2014.247","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073885","article-title":"Non hemorrhagic pericardial effusion from ibrutinib in a patient without comorbidities","volume":"28","author":"Aslan Cand\u0131r B","year":"2022","unstructured":"Aslan Cand\u0131r B, Yi\u011feno\u011flu TN, K\u0131z\u0131l \u00c7akar M, Dal MS, Altunta\u015f F. Non hemorrhagic pericardial effusion from ibrutinib in a patient without comorbidities. J Oncol Pharm Pract. 2022, 28:972-4. 10.1177\/10781552211073885","journal-title":"J Oncol Pharm Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1738IM","article-title":"Ibrutinib-associated serositis in mantle cell lymphoma","volume":"199","author":"Styskel BA","year":"2019","unstructured":"Styskel BA, Lopez-Mattei J, Jimenez CA, Stewart J, Hagemeister FB, Faiz SA. Ibrutinib-associated serositis in mantle cell lymphoma. Am J Respir Crit Care Med. 2019, 199:e43-4. 10.1164\/rccm.201809-1738IM","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231171925","article-title":"Serositis causing pericardial and pleural effusions after eight years of maintenance ibrutinib for Waldenstrom's macroglobulinemia","author":"Johnson G","year":"2023","unstructured":"Johnson G, Baviriseaty N, Massanet N, Kooper J. Serositis causing pericardial and pleural effusions after eight years of maintenance ibrutinib for Waldenstrom's macroglobulinemia. J Oncol Pharm Pract. 2023, 10781552231171925. 10.1177\/10781552231171925","journal-title":"J Oncol Pharm Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-4-246","article-title":"Cardiac tamponade mimicking tuberculous pericarditis as the initial presentation of chronic lymphocytic leukemia in a 58-year-old woman: a case report","volume":"4","author":"Lin E","year":"2010","unstructured":"Lin E, Boire A, Hemmige V, et al.. Cardiac tamponade mimicking tuberculous pericarditis as the initial presentation of chronic lymphocytic leukemia in a 58-year-old woman: a case report. J Med Case Rep. 2010, 4:246. 10.1186\/1752-1947-4-246","journal-title":"J Med Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2779","article-title":"Atypical presentation of cardiac tamponade as a cause of acute liver injury: case report and review of literature","volume":"10","author":"Thaker S","year":"2018","unstructured":"Thaker S, Yazici C, Koppe S. Atypical presentation of cardiac tamponade as a cause of acute liver injury: case report and review of literature. Cureus. 2018, 10:e2779. 10.7759\/cureus.2779","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313702-hemorrhagic-pericardial-effusion-and-cardiac-tamponade-in-b-chronic-lymphocytic-leukemia-treated-with-ibrutinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:06:53Z","timestamp":1737641213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313702-hemorrhagic-pericardial-effusion-and-cardiac-tamponade-in-b-chronic-lymphocytic-leukemia-treated-with-ibrutinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.77872","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}